Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

167 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Guichard S, Hennebelle I, Bugat R, Canal P. Guichard S, et al. Among authors: canal p. Biochem Pharmacol. 1998 Mar 1;55(5):667-76. doi: 10.1016/s0006-2952(97)00541-8. Biochem Pharmacol. 1998. PMID: 9515577

When cells were first exposed to 5FU, the product of cellular CPT-11 concentrations versus time (CxT) was 6895 +/- 1020 pmol x hr/10(6) cells, while it was 3875 +/- 121 pmol x hr/10(6) cells with CPT-11 alone (p < 0.01). The same phenomenon was observed with SN-38: 148.

When cells were first exposed to 5FU, the product of cellular CPT-11 concentrations versus time (CxT) was 6895 +/- 1020 pmol x hr/10(6) cell …
Toxicity patterns of cytotoxic drugs.
Chatelut E, Delord JP, Canal P. Chatelut E, et al. Among authors: canal p. Invest New Drugs. 2003 May;21(2):141-8. doi: 10.1023/a:1023565227808. Invest New Drugs. 2003. PMID: 12889735 Review.
Population pharmacokinetics of oxaliplatin.
Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E. Delord JP, et al. Among authors: canal p. Cancer Chemother Pharmacol. 2003 Feb;51(2):127-31. doi: 10.1007/s00280-002-0550-3. Epub 2002 Dec 4. Cancer Chemother Pharmacol. 2003. PMID: 12647013
Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R, Canal P. Arnould S, et al. Among authors: canal p. Biochem Pharmacol. 2002 Oct 15;64(8):1215-26. doi: 10.1016/s0006-2952(02)01291-1. Biochem Pharmacol. 2002. PMID: 12234602
Individual adaptive dosing of topotecan in ovarian cancer.
Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Déporte-Féty R, Bugat R, Canal P, Chatelut E. Montazeri A, et al. Among authors: canal p. Clin Cancer Res. 2002 Feb;8(2):394-9. Clin Cancer Res. 2002. PMID: 11839654 Clinical Trial.
Non-linear pharmacokinetics of irinotecan in mice.
Rouits E, Guichard S, Canal P, Chatelut E. Rouits E, et al. Among authors: canal p. Anticancer Drugs. 2002 Jul;13(6):631-5. doi: 10.1097/00001813-200207000-00010. Anticancer Drugs. 2002. PMID: 12172509
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C. Balin-Gauthier D, et al. Among authors: canal p. Cancer Chemother Pharmacol. 2006 Jun;57(6):709-18. doi: 10.1007/s00280-005-0123-3. Epub 2005 Dec 1. Cancer Chemother Pharmacol. 2006. PMID: 16320055
Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.
Delord JP, Léger F, Canal P, Poublanc M, Bugat R, Chatelut E. Delord JP, et al. Among authors: canal p. Cancer Chemother Pharmacol. 2006 Aug;58(2):189-94. doi: 10.1007/s00280-005-0142-0. Epub 2005 Nov 22. Cancer Chemother Pharmacol. 2006. PMID: 16328415 Clinical Trial.
[Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
Gladieff L, Chatelut E, Gaspard MH, Skaf R, de Forni M, Mihura J, Canal P, Bugat R. Gladieff L, et al. Among authors: canal p. Bull Cancer. 1999 Jul-Aug;86(7-8):673-7. Bull Cancer. 1999. PMID: 10477384 French.
Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans.
Guimbaud R, Guichard S, Dusseau C, Bertrand V, Aparicio T, Lochon I, Chatelut E, Couturier D, Bugat R, Chaussade S, Canal P. Guimbaud R, et al. Among authors: canal p. Cancer Chemother Pharmacol. 2000;45(6):477-82. doi: 10.1007/s002800051022. Cancer Chemother Pharmacol. 2000. PMID: 10854135
In inflammatory colon tissue (ulcerative colitis or Crohn's disease), DPD activity was significantly higher than in normal tissue (P = 0.006). In liver metastases from colon cancer, DPD activity was not significantly different from that observed in primary colon tumour ( …
In inflammatory colon tissue (ulcerative colitis or Crohn's disease), DPD activity was significantly higher than in normal tissue (P
167 results
Jump to page
Feedback